3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Myeloid, Accelerated Phase
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia
5
Blast Crisis
5
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
2
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Burkitt Lymphoma
1
Bone Marrow Diseases
1
Interventions
fludarabine
7
Whole-Body Irradiation
6
Cyclophosphamide
6
venetoclax
5
fludarabine phosphate
5
Tacrolimus
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Busulfan
4
asciminib
3
gilteritinib
2
blinatumomab
2
aldesleukin
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Interleukin-2
2
Idarubicin
2
Cytarabine
2
Bone Marrow Transplantation
2
Azacitidine
2
ponatinib
1
nilotinib
1
nicotinamide-beta-riboside
1
methanesulfonic acid
1
enasidenib
1
Thiotepa
1
Stem Cell Transplantation
1
Social Determinants of Health
1
Sirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid
×
ponatinib
×
1 year
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts